– USA, FL – Sun BioPharma, Inc., (OTCPink:SNBP), a biopharmaceutical company developing therapies for pancreatic diseases whose lead product candidate, SBP-101, has recently entered first in human clinical trials, today announced the appointment of Dr. Dalvir S. Gill to the Company’s Board of Directors. Dr. Gill will assume the Board seat currently held by Dr. Thomas Neenan who has resigned in order to increase the number of independent directors. The appointment and resignation are effective immediately and increases the number of independent directors to five of the eight member board.
“Dalvir’s successful track record and biopharmaceutical industry knowledge and thought leadership is a significant addition to our Board,” said Dr. Michael T. Cullen, Executive Chairman of Sun BioPharma. “His international clinical research & development background in multiple therapeutic areas and all phases of drug development will provide immeasurable insight as we continue to enroll patients for our pancreatic cancer Phase 1 clinical study of SBP-101 in Australia and later this year in the US.”
“The Board of Directors, on behalf of all stakeholders of Sun BioPharma, wishes to thank Thomas for his valuable business, scientific and technical contributions, and his time, effort and dedication as a Board member. Thomas will continue as our Chief Scientific Officer and will continue to advise the Board on a number of critical matters as we move forward.”
Dr. Dalvir Gill currently serves as the Chief Executive Officer of TransCelerate BioPharma Inc., a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community. Previously, Dr. Gill was President, Phase II-IV Development of InVentiv Health, and was Chief Operating Officer, of PharmaNet. Dr. Gill received a Ph.D. in Pathobiology from The Faculty of Medicine, University of London, a B.Sc from the University of Hertfordshire, and holds a diploma in the Health Economics of Pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has authored over 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.
About Sun BioPharma
Sun BioPharma, Inc. is a clinical stage biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are targeted to diseases of the pancreas, including pancreatitis and pancreatic cancer, and the Company’s initial product candidate is SBP-101 for the treatment of patients with pancreatic cancer. Sun BioPharma has scientific collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, Translational Genomics (TGen) in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, the University of Miami, the Austin Health Cancer Trials Centre, the Box Hill Hospital in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.